+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 75Years
All Genders
ID07850869

Real-World Study of Intratumoral H101 Oncolytic Virus with Immune Checkpoint Inhibitors for Advanced Metastatic Breast Cancer

Led by Jie Yuan,MD · Updated on 2026-09-30

15

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of intratumoral H101 oncolytic virus combined with immune checkpoint inhibitors ICIs in patients with advanced Stage IV breast cancer who have not responded to multiple prior treatments. This prospective, single-center, open-label, real-world observational study aims to preliminarily assess the antitumor activity, safety, and changes in the tumor immune microenvironment caused by this combination therapy in 10 to 15 patients aged 18 to 75 years with measurable and injectable lesions. The treatment framework includes 2- to 3-week cycles for a total of 4 planned cycles. On day 1 of each cycle, H101 is injected directly into tumors, with the dose adjusted by lesion size. ICIs, including anti-PD-1 and optionally anti-CTLA-4 antibodies, are infused intravenously 7 2 days after the H101 injection. The exact regimen is decided by physicians based on individual patient status and multidisciplinary advice. Tumor biopsies and blood samples are collected before treatment and after 4 cycles to analyze immune cell changes and gene expression. Participants undergo regular assessments including radiographic evaluations starting 6-8 weeks after treatment completion and every 3 months thereafter for up to one year or until disease progression. Safety is monitored through adverse event reporting using standardized criteria. Researchers measure outcomes such as objective tumor response, local lesion control, disease control rate, progression-free survival, and immune environment changes. The study includes comprehensive follow-up and data protection to ensure participant safety and scientific rigor.

CONDITIONS

Brief Title

A Real-World Observational Study of Intratumoral H101 Oncolytic Adenovirus Combined With Immune Checkpoint Inhibitors for Advanced Metastatic Breast Cancer

Research Team

J

Jie Yuan, Doctoral degree

J

Jie Yuan

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here